JAC Advance Access originally published online on July 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 145-148
© 2003 The British Society for Antimicrobial Chemotherapy
Leading Article |
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
1 Klinisk mikrobiologi, Centrallasarettet, 351 85 Växjö, Sweden; 2 Clinical Microbiology and Public Health Laboratory, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QW; 4 Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK; 3 Laborataire de Microbiologie Médicale, Hôpital Saint-Joseph, 185 rue Raymond Losserand, F-75014 Paris, France; 5 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital C-70, Weg door Jonkerbos 100, 6532 sz Nijmegen, The Netherlands; 6 Institut für Medizinische Mikrobio der Universitat Leipzig, Liebigstr 24, Leipzig 04103, Germany; 7 Department of Microbiology, Akershus University Hospital, P.O. Box 23, N-1474 Nordbyhagen, Norway; 8 National Reference Laboratory for Antibiotics, National Institute of Public Health, Srobarova 48, 100 42 Prague 10, Czech Republic; 9 Dept of Hygiene & Epidemiology, Medial School, Athens University, 75 M.Asias Str, GR-11527 Athens (Goudi), Greece
Keywords: EUCAST, breakpoints, antibiotic resistance
| The first 150 words of the full text of this article appear below. |
The success or failure of antimicrobial therapy in bacterial and fungal infections is predicted ideally by antimicrobial susceptibility testing (AST), in which microorganisms are divided into treatable and non-treatable categories on the basis of MIC breakpoints. In Europe, the categorization was traditionally a clinical one and it was made irrespective of whether or not the organism harboured resistance mechanisms. MIC breakpoints generally divide bacteria into three categories of susceptibility: susceptible, intermediate or indeterminate, or resistant. These terms can be defined as susceptible (S—where the antimicrobial activity is associated with a likelihood of therapeutic success), intermediate or indeterminate (I—where the antimicrobial activity is associated with an indeterminate or uncertain therapeutic effect) and resistant (R—where the antimicrobial activity is associated with a higher than expected likelihood of therapeutic failure). MIC breakpoints are used either directly, as in MIC determination and ‘breakpoint’ susceptibility testing methods in broth or agar, or indirectly when converted
 |
Acknowledgements |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Pfaller, D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, A. Espinel-Ingroff, C. L. Fowler, et al. Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods J. Clin. Microbiol., October 1, 2009; 47(10): 3142 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. de Jong, R. Bywater, P. Butty, E. Deroover, K. Godinho, U. Klein, H. Marion, S. Simjee, K. Smets, V. Thomas, et al. A pan-European survey of antimicrobial susceptibility towards human-use antimicrobial drugs among zoonotic and commensal enteric bacteria isolated from healthy food-producing animals J. Antimicrob. Chemother., April 1, 2009; 63(4): 733 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Arendrup, G. Kahlmeter, J. L. Rodriguez-Tudela, and J. P. Donnelly Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1628 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. DeFife, M. H. Scheetz, J. M. Feinglass, M. J. Postelnick, and K. K. Scarsi Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1074 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Desnos-Ollivier, F. Dromer, and E. Dannaoui Detection of Caspofungin Resistance in Candida spp. by Etest J. Clin. Microbiol., July 1, 2008; 46(7): 2389 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Frei, N. P. Wiederhold, and D. S. Burgess Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation J. Antimicrob. Chemother., March 1, 2008; 61(3): 621 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Simjee, P. Silley, H. O. Werling, and R. Bywater Potential confusion regarding the term 'resistance' in epidemiological surveys J. Antimicrob. Chemother., January 1, 2008; 61(1): 228 - 229. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Hayward, K. Goldsmith, A. M. Johnson, and on behalf of the Surveillance Subgroup of SACAR Report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Surveillance Subgroup J. Antimicrob. Chemother., August 1, 2007; 60(suppl_1): i33 - i42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kronvall, I. Karlsson, M. Walder, M. Sorberg, and L. E. Nilsson Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation J. Antimicrob. Chemother., March 1, 2006; 57(3): 498 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sunde Prevalence and characterization of class 1 and class 2 integrons in Escherichia coli isolated from meat and meat products of Norwegian origin J. Antimicrob. Chemother., December 1, 2005; 56(6): 1019 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mork, T. Tollersrud, B. Kvitle, H. J. Jorgensen, and S. Waage Comparison of Staphylococcus aureus Genotypes Recovered from Cases of Bovine, Ovine, and Caprine Mastitis J. Clin. Microbiol., August 1, 2005; 43(8): 3979 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sunde and M. Norstrom The genetic background for streptomycin resistance in Escherichia coli influences the distribution of MICs J. Antimicrob. Chemother., July 1, 2005; 56(1): 87 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Q. Liu, Y. Z. Zhang, and P. J. Gao Novel Concentration-Killing Curve Method for Estimation of Bactericidal Potency of Antibiotics in an In Vitro Dynamic Model Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3884 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Eaves, L. Randall, D. T. Gray, A. Buckley, M. J. Woodward, A. P. White, and L. J. V. Piddock Prevalence of Mutations within the Quinolone Resistance-Determining Region of gyrA, gyrB, parC, and parE and Association with Antibiotic Resistance in Quinolone-Resistant Salmonella enterica Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4012 - 4015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Smith, A. M. Noreddin, C. G. Siemens, K. N. Schurek, J. Greisman, C. J. Hoban, D. J. Hoban, and G. G. Zhanel Designing Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3630 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Mouton, A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141 Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1713 - 1718. [Abstract] [Full Text] [PDF]
|
|